Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008;51(15):4632–40.
Article
CAS
PubMed
Google Scholar
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.
Article
CAS
PubMed
Google Scholar
Van Der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. PALETTE: final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. ASCO Meeting Abstracts. 2012;30(15_suppl):10009.
Google Scholar
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.
Article
CAS
PubMed
Google Scholar
Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. European journal of cancer (Oxford, England : 1990). 2013;49(6):1287–96.
Article
CAS
Google Scholar
SmPC pazopanib (Votrient) [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf].
Oliva E, Carcangiu ML, Carinelli SG, Ip P, Loening T, Longacre TA, Nucci MR, Prat J, Zaloudek CJ. Mesenchymal tumours. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. Pathology and genetics of Tumours of female reproductive organs. 4th ed. Lyon: IARC; 2014. p. 141–5.
Google Scholar
Ali RH, Rouzbahman M. Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. J Clin Pathol. 2015;68(5):325–32.
Article
PubMed
Google Scholar
Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic review. Obstet Gynecol. 2013;122(3):676–83.
Article
PubMed
Google Scholar
Lee CH, Marino-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, Gilks CB, van de Rijn M, Oliva E, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53.
Article
PubMed
Google Scholar
Lee C-H, Hoang LN, Yip S, Reyes C, Marino-Enriquez A, Eilers G, Tao D, Chiang S, Fletcher JA, Soslow RA, et al. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Mod Pathol. 2014;27(5):751–7.
Article
CAS
PubMed
Google Scholar
Chan JK, Kawar NM, Shin JY, Osann K, Lm C, Powell CB, Kapp DS. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99(8):1210–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Geel RMJM, Beijnen JH, JHM S. Concise drug review: Pazopanib and Axitinib. Oncologist. 2012;17(8):1081–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shah R, Morganroth J, Shah D. Hepatotoxicity of tyrosine Kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503.
Article
CAS
PubMed
Google Scholar
Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB. Severe Pazopanib-induced Hepatotoxicity: clinical and Histologic course in two patients. J Clin Oncol. 2012;30(27):e264–8.
Article
PubMed
Google Scholar
Vlenterie M, van Erp NP, van der Graaf WTA. Promising management of pazopanib-induced liver toxicity. Acta Oncol. 2015;54(7):1064–6.
Article
PubMed
Google Scholar
Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, et al. HLA-B*57:01 confers susceptibility to Pazopanib-associated liver injury in patients with cancer. Clin Cancer Res. 2016;22(6):1371–7.
Article
CAS
PubMed
Google Scholar
de Wit D, den Hartigh J, Gelderblom H, Qian Y, den Hollander M, Verheul H, Guchelaar HJ, van Erp NP. Dried blood spot analysis for therapeutic drug monitoring of pazopanib. J Clin Pharmacol. 2015;55(12):1344–50.
de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, Guchelaar HJ, Verheul HM, Gelderblom H. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37(3):331–8.
Article
CAS
PubMed
Google Scholar
Sardinha R, Hernandez T, Fraile S, Tresserra F, Vidal A, Gomez MC, Astudillo A, Hernandez N, Saenz de Santamaria J, Ordi J, et al. Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors. Clin Sarcoma Res. 2013;3(1):3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C. A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol. 2006;101(3):545–7.
Article
PubMed
Google Scholar
Kalender M, Sevinc A, Yilmaz M, Ozsarac C, Camci C. Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol. 2009;63(3):555–9.
Article
PubMed
Google Scholar
Verschoor AJ, Gelderblom H. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clin Sarcoma Res. 2014;4:14.
Article
PubMed
PubMed Central
Google Scholar